Abcellera Biologics Inc ABCL

$11.88 +0.75 (6.74%)

Valuation

Market cap
3,642,539,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,210,600
Avg volume
4,428,534
Day's range
$11.20 – $11.98
Shares out
306,611,000
Stochastic %K
36%
Beta
1.59
Analysts
Strong Buy
Price target
$17.17

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

ajmore Nov 8, 6:29 PM
$ABCL will Abcelera end up gobbled up like Metsera! Candidates: Lilly, PfizerAstra, Abbvie, Merck. Drug: antibody for reducing flushes post menopause and post hormonal treatment after breast cancer and after prostate cancer treatments. Premium: 200% Its the next blockbuster drug. Abceleras drug is more tolerable, a subcutaneous injection once every 3 months, very tolerable. OLE is going strong. Target: 35 acquisition, 65-100 USD long term. Acquirer will be tempted as Abcelera have a pipeline and a platform.
0 replies
Jwa68 Nov 8, 5:58 PM
$GANX Ray is a good guy and has made investors who followed him over the years a lot of money for the most part. His newsletter is not cheap and rightfully so. He is known for finding opportunities early, just like he did recommending $NVDA at 3. That type of forsight makes any newsletter money very well spent. Note the other 3 pics he recommended early back in 24.$ROIV is up huge, the other not too shabby. Ironically he recommended $ABCL which I mentioned a few months back and has now over doubled. Joe already posted some of his recent writeup, but not the good stuff. Nonetheless, this one is deeply personal with his mom having Parkinson's. He knows the disease, and all the drugs before rexacerat. Few are more educated, knowledgeable or better positioned to offer an opinion. This is not a random anonymous Stocktwits poster, rather a fairly well respected and completely objective third party biotech analyst with a long time track record of finding large winners in the space.
3 replies
Stocktradesmoon Nov 8, 3:04 PM
$ABCL $HIMS $SLS $SYRE $REGN Interesting observation for $ABCL and ABCL688. Looking back at ABCL575’s Phase 1 trial registration: • July 24, 2025: Submitted to http://ClinicalTrials.gov • July 25: Trial officially started • August 5: Registration passed quality review • August 7: Registration became publicly available That’s 13 days between the trial’s actual start date and its public listing. It’s entirely plausible that ABCL688 could be further along and has started Phase1/2…. 👀 Add in the recent wording change on AbCellera’s pipeline website.. you never know. 👀 Tomorrow is going to be much more interesting! 🚀🚀🚀 Long and strong!
1 replies
Merlintrader Nov 8, 9:27 AM
$ABCL: Q3 results Mon Nov 9, call 5:00 PM ET. Webcast: https://investors.abcellera.com/events/default.aspx Fri close $11.88, below SMA50 ($12.28), above SMA200 ($7.04), RSI 48. Interactive chart with bull/bear scenarios: https://justcharts.merlintrader.com/#ABCL Hub: https://www.merlintrader.com/abcellera-biologics-stock-hub/ Not investment advice.
0 replies
Stocktradesmoon Nov 7, 11:01 PM
$ABCL $HIMS $REGN $PFE $MRNA $ABCL prints Monday. A biotech with a platform, not a product, is valued on the pipeline. The print is a cash check, not a revenue check.
0 replies
Jwa68 Nov 7, 10:24 PM
$ABCL Has been incredibly resilient in an abysmal market. Typically the type of stock worth owning when the market normalizes.
0 replies
Stocktradesmoon Nov 7, 6:45 AM
$ABCL $HIMS $SLS $SYRE $REGN "The only way to get your break is to keep showing up, keep grinding and keep finding a way to make it to another practice until luck finds you." - Danny Amendola, undrafted super bowl champion
0 replies
GTA_Terminal Nov 7, 3:44 AM
Dark pool check on $ABCL: what traded off the exchanges this session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=ABCL&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=ABCL Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-abcellera-biologics-abcl-2?utm_source=stocktwits&utm_medium=social
0 replies